. Until the eighties, attempts to treat widespread diseases were not successful and renal cancer is considered as a radio-resistant and chemoresistant tumour (Finney, 1973; Droz et al., 1988 The characteristics of the 25 eligible patients are detailed in Table I . There were 16 males and nine females; median age was 69 (range 65-77). None of them had received prior treatment except surgery (23 nephrectomy/25).
Although renal cell carcinoma is a relatively rare tumour, its natural history has at least two remarkable points, i.e. the highest incidence occurs at 65 years of age and 50 to 60% of the patients develop distant metastases (Holland, 1977; Ritchie et al., 1987) . Until the eighties, attempts to treat widespread diseases were not successful and renal cancer is considered as a radio-resistant and chemoresistant tumour (Finney, 1973; Droz et al., 1988) .
Therefore, the 30% response rate, with 10% complete response in patients treated by intravenous recombinant Interleukin-2 (IL2) first reported by Rosenberg et al. (1987) , was considered as a possible breakthrough in this disease. Further studies, though with a generally lower dose of IL2 and lower response rate, unequivocally confirmed the activity of IL2 in metastatic renal cell carcinoma (West et al., 1987; Negrier et al., 1990 (Miller et al., 1981 
100%
For each patient, the maximum severity through the successive cycles is considered. All these toxicities were evaluated as grade 1 to 3 (WHO). dopamine infusions in two cases and requested interruption of the therapy in one. Fever was present in all patients but routinely well controlled by acetaminophen; the use of indomethacin was restricted to a few cases (e.g. two patients). Gastro-intestinal signs of moderate severity were commonly observed; in three patients, however, vomiting and diarrhoea required dose modifications at almost each successive course. Weight gain below 5% was observed in 15 patients, but only two patients overloaded 10% of their basal weight. Renal toxicity was of great concern with a rise of creatinine levels over 300 lAg 1-' in 18/25 patients but dose modification was required in a few cases only (i.e. 2/25). Hepatic and haematological disturbances were also frequent but always transient and moderate. Of note, the number of transfusional requirements was particualarly low, i.e. four red blood cell transfusions and no platelet transfusion.
Once treatment was completed all toxicities of rIL2 resolved within 1 to 2 weeks leaving no residual deficit.
Response to therapy Three patients were not evaluable i.e. one early withdrawal (after 4 days of treatment for catheter-related complications), one toxic death and one patient who was considered a posteriori not to have significant measurable lesions (<1 cm). Evaluation of the 22 remaining patients showed one partial and two complete responses, giving an overall response rate of 3/25 with three responders in 22 evaluable patients. Details of responding patients are shown in Table  V . In the two patients who are in complete remission a partial response (i.e. more than 50% tumour regression) was already achieved after the two induction courses; the disappearance of all lesions was observed respectively after two and four maintenance cycles. Eight patients were considered as stable disease respectively for 4 +, 6, 6 +, 7, 7 +, 9, 11 + and 12 + months and 11 patients were progressive. Two patients classified as stable had indeed tumour regression. In one patient five pulmonary metastatic nodules disappeared whereas one residual lesion slightly increased in size (increase <25%). This patient, because of the occurrence of severe hypotension during IL2 therapy, refused to carry on treatment. He then received alpha Interferon (18 x 106 U thrice a week) and the residual mass was reduced by approximately 75%. The status of this patient has remained stable for 11 months. In another patient two metastatic abdominal lymph nodes disappeared whereas bone lesions were stable on radiolabelled bone scan. The status of the patient has been unchanged for 12 months.
Discussion
This is, to our knowledge, the first report of IL2 therapy in a group of patients of more than 65 years with renal cell carcinoma. Since the potential impairments or failure of different organs are of great concern in this particular population, the schedule described by West et al., 1987 , was used in a view to reduce toxicity. The amount of drug administered was over 70% of the planned dose in almost all the patients during the first course. Types of toxicities observed were comparable to what had been observed in younger patients and mostly manageable using symptomatic treatments and transient interruptions of rIL2 infusion. However, cardiac toxicity was of great concern; cardiac rhythm disturbances occurred in 44% of the patients and cardiac toxicity was clearly involved in the toxic death. Although cardiac toxicity of IL2 was already known and anlaysed, such a severity and incidence were not commonly reported in previous studies, specially when continuous infusion was used (Rosenberg et al., 1987; West et al., 1987; Fischer et al., 1988; Nora et al., 1989; Negrier et al., 1990; Siegel et al., 1991) . Obviously, despite normal cardiologic tests prior to treatment, the heart of patients over 65 is particularly sensitive to IL2 toxicity. As in previous reports (Rosenberg et al., 1987; West et al., 1987; Fischer et al., 1988; Nora et al., 1989; Negrier et al., 1990) fever, hypotension and renal failure were the most common other side effects encountered. They also appeared transient and limited to the treatment period. Three responses were seen and two complete remissions were achieved i.e. two durable persistent complete responses and one partial response. In addition, among the eight patients categorised as stable, two patients also had significant persistent tumour regressions.
These results are not different from those reported in cohorts of younger patients (Rosenberg et al., 1987; Fischer et al., 1988; Nora et al., 1989; Negrier et al., 1990) .
IL2 therapy which induces, according to different authors, a response rate of 20 to 30% is, in this respect, beneficial only to a minority of patients (Rosenberg et al., 1987; Fischer et al., 1988; Nora et al., 1989; Negrier et al., 1990 ). Nevertheless, the 5 to 10% complete response rate should not be disregarded in a disease in which nothing but rIL2 and Interferon alpha has really proved efficient (Quesada et al., 1985; Bergerat et al., 1988) . To an individual and ethical point of view, we think we have to give a maximum of patients the chance to reach complete remission through immunotherapy. Except for some preliminary data, no predictive factor of response is known yet; and our study indicates that age does not influence the potential of tumour regression induced by in vivo IL2 stimulation (Blay et al., 1990) .
However, the schedule of treatment and the drugs to use, i.e. rIL2 vs IFN vs both of them, are still debatable. Prior studies reported interesting results with ambulatory therapy with Interferon, but the duration of these treatment schedules, i.e. 6 to 12 months, is not adapted to a disease with a crude median survival of 8 to 12 months (Ritchie et al., 1987; Deforges et al., 1988; Elson et al., 1988; Philip et al., 1989) . More recently, a 'home therapy regimen' was proposed using a subcutaneous combination of rIL2 and Interferon alpha (Atzpodien et al., 1990) . This regimen did not raise any life threatening toxicity and the response rate obtained does not signficantly differ from those obtained with continuous infusion of IL2. To our point of view, a first line immunotherapy should be proposed to a maximum of patients in order to select those who are sensitive to this kind of therapy, and long lasting schedules should be restricted to responding patients. As such, the combined subcutaneous schedules of IL2 and IFN could represent an adapted deal to this situation. Prolonged therapy in responding patients must be evaluated in randomised trials.
In conclusion, the present study demonstrates that rIL2 continuous infusion is feasible, but has a particular cardiac toxicity in patients over 65 years old. The efficacy of rIL2 in this group is not different from what it is in the general population of patients with metastatic renal cell cancer.
